Affinity DataKi: 0.0440nMAssay Description:Inhibition of Bcl2 (unknown origin)More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Boston University
Curated by ChEMBL
Boston University
Curated by ChEMBL
Affinity DataKi: 0.0800nMAssay Description:Inhibition of human DOT1-like Histone H3 Methyltransferase preincubated for 30 mins followed by 3H-SAM addition and measured after 120 minsMore data for this Ligand-Target Pair
Affinity DataKi: 0.400nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.450nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.490nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.5nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.510nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.520nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.540nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.560nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.600nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.600nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.620nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.620nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.620nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.640nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.650nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.680nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.680nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.690nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.700nMAssay Description:Inhibition of glucocorticoid receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 0.770nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.780nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.790nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.790nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 11/12/13/14(Homo sapiens (Human))
Boston University
Curated by ChEMBL
Boston University
Curated by ChEMBL
Affinity DataKi: 0.800nMAssay Description:Inhibition of P38 mitogen activated protein kinase (unknown origin)More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.800nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.800nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.840nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.850nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.850nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.860nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.880nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.910nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.920nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.960nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.990nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.990nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 1nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 1nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 1nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 1nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 1.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 1.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 1.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 1.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 1.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 1.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 1.20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 1.20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair